Back

Rare and Common Genetic Variants, Smoking and Higher Body Mass Index Are Associated with Earlier Age of Progression to Geographic Atrophy and Neovascular Advanced Stages of Macular Degeneration in a Prospective Analysis

Seddon, J.; Widjajahakim, R.; Rosner, B.

2020-08-15 ophthalmology
10.1101/2020.08.13.20174383
Show abstract

IMPORTANCEGenes and lifestyle factors influence progression to advanced age-related macular degeneration (AAMD). However, the impact of genetic and behavioral factors on age when this transition occurs has not been evaluated prospectively. OBJECTIVETo determine whether genetic and environmental factors are associated with age of progression to AAMD and to quantify the effect on age. DESIGN, SETTING, AND PARTICIPANTSLongitudinal progression to AAMD was based on the severity scale in the Age-Related Eye Disease Study database. Progression was defined as an eye that transitioned from non-advanced dry AMD without any evidence of geographic atrophy (GA) (levels 1-8) to any GA or evidence of neovascularization (NV) or both (levels [&ge;]9) during 13 years follow up. Genotypes were determined from DNA samples. MAIN OUTCOME AND MEASURESA stepwise selection of genetic variants with the eye as the unit of analysis, using age as the time scale, yielded 11 genetic variants associated with overall progression, adjusting for sex, education, smoking history, BMI, baseline severity scale, and AREDS treatment. Multivariate analysis was also performed to calculate the effect of genetic and behavioral factors on age of progression. RESULTSAmong 5421 eyes, 1206 progressed. Genetic variants associated with progression to AAMD were in the complement, immune, inflammatory, lipid, extracellular matrix, DNA repair and protein binding pathways. Three of these variants were significantly associated with earlier age of progression, adjusting for other covariates: CFH R1210C (P=0.019) with 4.7 years earlier age at progression among carriers of this mutation, C3 K155Q (P=0.011) with 2.44 years earlier for carriers, and ARMS2/HTRA1 A69S (P=0.012) with 0.67 years earlier per allele. Subjects who were smokers (P<. 001) or had high BMI (P=0.006) also had an earlier age at progression (4.1 years and 1.4 years, respectively). CONCLUSIONSCarriers of rare variants in the complement pathway and a common risk allele in ARMS2/HTRA1 develop advanced AMD at an earlier age, and unhealthy behaviors including smoking and higher body mass index lead to earlier age of progression to AAMD. KEY POINTSO_ST_ABSQuestionC_ST_ABSAre genetic and modifiable factors associated with earlier age of developing advanced AMD? FindingsIn this prospective analysis of 5421 eyes with non-advanced AMD at baseline, 1206 developed advanced stages of AMD. Smoking together with a higher BMI led to 5.5 years earlier progression to advanced disease, and genetic burden, determined by rare and common variants, lowered age of progression by up to an additional 6.0 years, adjusting for all covariates. MeaningModifiable factors alter age when advanced AMD and associated visual loss occurs, and genetic susceptibility impacts age of this transition. Results underscore the importance of both nature and nurture on earlier progression to advanced disease leading to a longer duration of disease and treatment burden. Submitted as ARVO abstract December, 2019: abstract citation: Widjajahakim R, Rosner B, Seddon J; Rare and Common Genetic Variants and Behavioral Modifiable Factors Are Associated with Earlier Age of Progression to Advanced AMD. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2436).

Matching journals

1
Investigative Opthalmology & Visual Science
Association for Research in Vision and Ophthalmology (ARVO) · based on 11 published papers
#1
335× avg
2
Ophthalmology Science
Elsevier BV · based on 15 published papers
Top 0.2%
150× avg
3
PLOS ONE
Public Library of Science (PLoS) · based on 1737 published papers
Top 41%
12.5%
4
Eye
Springer Science and Business Media LLC · based on 11 published papers
Top 0.3%
121× avg
5
Translational Vision Science & Technology
Association for Research in Vision and Ophthalmology (ARVO) · based on 18 published papers
Top 0.7%
51× avg
6
British Journal of Ophthalmology
BMJ · based on 13 published papers
Top 0.8%
57× avg
7
GeroScience
Springer Science and Business Media LLC · based on 22 published papers
Top 0.6%
30× avg
8
Scientific Reports
Springer Science and Business Media LLC · based on 701 published papers
Top 58%
2.6%
9
F1000Research
F1000 Research Ltd · based on 28 published papers
Top 2%
8.0× avg
10
eLife
eLife Sciences Publications, Ltd · based on 262 published papers
Top 19%
1.5%
11
PLOS Genetics
Public Library of Science (PLoS) · based on 39 published papers
Top 3%
9.5× avg
12
Nature Communications
Springer Science and Business Media LLC · based on 483 published papers
Top 34%
1.3%
13
Clinical and Translational Science
Wiley · based on 14 published papers
Top 2%
9.9× avg
14
International Journal of Molecular Sciences
MDPI AG · based on 39 published papers
Top 3%
6.5× avg
15
British Journal of Cancer
Springer Science and Business Media LLC · based on 22 published papers
Top 3%
5.7× avg
16
BMJ Open
BMJ · based on 553 published papers
Top 51%
0.8%
17
Human Genetics
Springer Science and Business Media LLC · based on 14 published papers
Top 2%
15× avg
18
Journal of Medical Genetics
BMJ · based on 22 published papers
Top 2%
10× avg
19
Journal of Allergy and Clinical Immunology
Elsevier BV · based on 15 published papers
Top 2%
8.2× avg
20
Communications Biology
Springer Science and Business Media LLC · based on 36 published papers
Top 5%
4.6× avg